Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
Ye Hu, Jiyue Gao, Meiling Wang, Man Li Department of Oncology & Department of Breast Surgery, The Second Hospital of Dalian Medical University, Dalian, People’s Republic of ChinaCorrespondence: Man LiDepartment of Oncology & Department of Breast Surgery, The Second Hospital of Dalian Medical...
Main Authors: | Hu Y, Gao J, Wang M, Li M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-07-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/potential-prospect-of-cdk46-inhibitors-in-triple-negative-breast-cance-peer-reviewed-fulltext-article-CMAR |
Similar Items
-
The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo
by: Lubaid Saleh, et al.
Published: (2023-04-01) -
Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer
by: Yajing Huang, et al.
Published: (2020-10-01) -
Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer
by: Mariya Yordanova, et al.
Published: (2021-12-01) -
CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer
by: Lubaid Saleh, et al.
Published: (2021-12-01) -
Facts and prospects of peptide in targeted therapy and immune regulation against triple-negative breast cancer
by: Yongxiu Huang, et al.
Published: (2023-08-01)